Relay Therapeutics (RLAY) Current Deferred Revenue (2021 - 2024)

Relay Therapeutics (RLAY) has 4 years of Current Deferred Revenue data on file, last reported at $7.7 million in Q4 2024.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $7.7 million in Q4 2024; TTM through Dec 2024 was $7.7 million, a N/A change from a year earlier, with the FY2024 full-year figure at $7.7 million, changed N/A from the prior year.
• Current Deferred Revenue for Q4 2024 stood at $7.7 million, up from $24000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for RLAY reached as high as $7.7 million in Q4 2024 and fell as low as $15000.0 in Q2 2023.
• Historically, Current Deferred Revenue has averaged $1.1 million across 4 years, with a median of $207000.0 in 2021.
• Across the five-year window, Current Deferred Revenue slumped 79.95% in 2022 and tumbled 81.93% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $248000.0 in 2021, then plunged by 66.53% to $83000.0 in 2022, then tumbled by 71.08% to $24000.0 in 2023, then soared by 31895.83% to $7.7 million in 2024.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $7.7 million in Q4 2024, $24000.0 in Q3 2023, and $15000.0 in Q2 2023.